Cathy Klema
CIK 1181157 · last filed 2026-06-10
Cathy Klema is a corporate insider who has filed 36 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for OPRX, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions. 20 SEC filings were submitted jointly with PHARMACEUTICAL PRODUCT DEVELOPMENT INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
WPI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OPRX | Director | 56,137 | $9.07 | $509.2K | $0 | 5 | 2026-06-10 |
| Allergan plc (AGN) Delisted | Director | 25,081 | — | — | $0 | 7 | 2019-05-02 |
| ACT | Director | 21,027 | $48.29 | $1.02M | $0 | 2 | 2015-06-08 |
| Actavis, Inc. (WPI) Delisted | Director | 44,432 | — | — | -$1.70M | 7 | 2012-08-01 |
| PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted | Director | 16,199 | — | — | -$774.3K | 12 | 2011-01-04 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | OPRX | Grant (A) | +34,517 | $0 | EDGAR |
| 2025-06-12 | OPRX | Grant (A) | +9,868 | $0 | EDGAR |
| 2025-02-04 | OPRX | Exer (M) | +5,109 | $0 | EDGAR |
| 2024-06-11 | OPRX | Grant (A) | +6,643 | $0 | EDGAR |
| 2024-02-06 | OPRX | Grant (A) | — | $0 | EDGAR |
| 2019-05-02 | Allergan plc (AGN) Delisted | Tax (F) | −953 | -$140.1K | EDGAR |
| 2019-03-13 | Allergan plc (AGN) Delisted | Other (J) | +410 | $0 | EDGAR |
| 2018-05-04 | Allergan plc (AGN) Delisted | Grant (A) | +1,985 | $299.9K | EDGAR |
| 2017-05-05 | Allergan plc (AGN) Delisted | Grant (A) | +1,223 | $299.9K | EDGAR |
| 2016-08-09 | Allergan plc (AGN) Delisted | Grant (A) | +201 | $49.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.